Cargando…
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
BACKGROUND: Metastatic melanoma is a highly chemotherapy resistant tumour. The use of newer targeted therapies alone and in combination with chemotherapy may offer new hope of improving response to treatment. Dasatinib, a multi-target kinase inhibitor, is currently approved for the treatment of chro...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2569026/ https://www.ncbi.nlm.nih.gov/pubmed/18823558 http://dx.doi.org/10.1186/1479-5876-6-53 |